New York, United States
H1 is a biotechnology and healthcare startup based in the United States, established in 2017. The company's slogan, "H1 is the connecting force for global HCP, clinical, scientific and research information," reflects its mission to democratize access to critical expertise, HCP information, claims data, and groundbreaking research for doctors, researchers, industry professionals, and ultimately, patients.
H1's last investment amounted to $10.00M in Debt Financing, which was secured on 13 June 2022. This funding is expected to further propel the company's efforts in advancing medicine and clinical outcomes, as well as accelerating the development, launch, and dissemination of life-saving treatments. Despite not having specified investors for the latest funding round, H1's innovative solutions have the potential to drive meaningful engagements with key opinion leaders and ensure equitable access to healthcare services.
Through its efforts, H1 aims to create a healthier future worldwide and bring together all stakeholders in the healthcare ecosystem to foster collaboration and ultimately improve patient outcomes.
Paradigm Health
